Investigational drug for treatment of advanced Non-Small Cell Lung Cancer
Michael P. Kosty, M.D.
This study will test the safety of an investigational oral drug, BBP-398, combined with an FDA approved dose of Nivolumab. The purpose of this Phase I study is to find a safe dose range of BBP-398 that can be given to patients with non-small cell lung cancer.
Be 18 years or older
Have documentation of a KRAS mutation
Be willing to record daily intake of study drug in diary
Be able to swallow oral medication
Patients must not:
Have history of significant cardiovascular disease
Have undergone major surgery within 4 months of starting treatment
Have a history of allogenic bone marrow transplant
All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines (Geisel Pavilion).
Search NCT05375084 at https://clinicaltrials.gov website for more information.